Dexcom G5 Continuous Glucose Monitoring System Now Available on Mobile, Smart Devices for Medicare Patients with Diabetes
June 11 2018 - 6:28PM
Business Wire
Dexcom is the only CGM proven to significantly
reduce A1C
Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose
monitoring for people with diabetes, announced today the U.S.
Centers for Medicare & Medicaid Services (CMS) is updating its
policy on mobile device compatibility for the Dexcom G5® CGM
System. Available on iOS and Android, the Dexcom G5 is the first
and only mobile-enabled CGM system for Medicare patients with
diabetes that works to display and share real-time glucose
activity.
The CMS announcement states:
Medicare’s published coverage policy for CGMs will be modified
to support the use of CGMs in conjunction with a smartphone,
including the important data sharing function they provide for
patients and their families.
“On behalf of our Medicare population, Dexcom would like to
recognize and thank CMS for this policy coverage update,” said
Kevin Sayer, President and CEO of Dexcom. “This update allows
patients to access the full functionality of the Dexcom G5 CGM
system as approved by the Food and Drug Administration (FDA). By
doing what is right for the patient, CMS is creating value for the
entire healthcare system.”
“We would also like to recognize the diabetes community for
their efforts in voicing the necessity for this change. CMS
listened and recognized the need to allow the sharing of glucose
data in this population,” said Claudia Graham, SVP of Global
Access.
As the first therapeutic CGM approved by CMS in January 2017,
the Dexcom G5 Mobile System provides Medicare patients with
highly-accurate glucose readings sent every five minutes from a
sensor worn just underneath the skin to a compatible smart device
or receiver. The Dexcom G5 Mobile System offers Medicare patients
life-saving safety and privacy features that no other CGM product
provides, including proactive alerts and alarms.
With nearly half of adults ages 65 and up using smartphones,
Medicare diabetes patients are now able to use the Dexcom Share
feature that allows users to share glucose information with up to
five loved ones or caregivers.
HOW MOBILE WORKSCurrent and eligible Medicare patients
can download the Dexcom G5 Mobile app to compatible iOS and Android
devices via iTunes and Google Play, and login into their Dexcom
account. Dexcom G5 is compatible with the iPhone X, 8, 7 and 6, in
addition to 14 of the top 30 Android phones. It’s also compatible
with the Apple Watch and Android Wear Watches. A current list of
compatible devices can be found at dexcom.com/compatibility.
About CGMCGM devices are considered the most
significant breakthrough in diabetes management in the past 40
years1 and Dexcom has been a leader of those
innovations. Diabetes affects nearly 30 million Americans and is
the seventh leading cause of death in the United States2. The
traditional standard-of-care for glucose monitoring has been a
fingerstick meter, which is painful as some patients needed to test
their blood up to 12 times a day. CGM is important because, in
addition to providing the glucose level, it provides the direction
and rate of glucose change with the push of a button and alerts
users when glucose levels are too low or too high. People with
diabetes who take insulin must monitor their blood glucose levels
frequently. Uncontrolled glucose can cause health complications and
even death3,4. To learn more about CGM,
visit www.dexcom.com.
About Dexcom, Inc.Dexcom, Inc., headquartered
in San Diego, CA, is dedicated to helping people better manage
their diabetes by developing and marketing continuous glucose
monitoring (CGM) products and tools for adult and pediatric
patients. With exceptional performance, patient comfort and
lifestyle flexibility at the heart of its technology, users have
consistently ranked Dexcom highest in customer
satisfaction and loyalty. For more information on the Dexcom CGM,
visit www.dexcom.com.
References1. Clarke SF and Foster JR. A history of
blood glucose meters and their role in self-monitoring of diabetes
mellitus. Br J Biomed Sci. 2012;(3)2:83-93.2. 2014 National
Diabetes Statistics Report. Centers for Disease Control and
Prevention. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf Accessed March
31, 2015.3. Hyperglycemia (High blood glucose). American
Diabetes Association Web
site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.
Updated August 5, 2013. Accessed December 3,
2013.4. Hypoglycemia (Low blood glucose). American
Diabetes Association Web
site. http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.
Updated July 16, 2013. Accessed December 3, 2013.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180611006280/en/
Dexcom, Inc.INVESTOR CONTACT:Steve Pacelli,
858-200-0200orPRESS CONTACT:James McIntosh, 619-884-2118
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2023 to Apr 2024